Montanaro Asset Management Ltd lowered its holdings in Bruker Co. (NASDAQ:BRKR - Free Report) by 4.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 426,950 shares of the medical research company's stock after selling 19,550 shares during the quarter. Bruker accounts for about 5.2% of Montanaro Asset Management Ltd's holdings, making the stock its 2nd biggest position. Montanaro Asset Management Ltd owned about 0.28% of Bruker worth $25,028,000 as of its most recent filing with the SEC.
Several other institutional investors also recently made changes to their positions in the stock. FMR LLC grew its holdings in shares of Bruker by 21.4% in the 3rd quarter. FMR LLC now owns 14,306,122 shares of the medical research company's stock worth $987,981,000 after acquiring an additional 2,521,904 shares during the period. Vaughan Nelson Investment Management L.P. grew its holdings in Bruker by 140.3% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company's stock valued at $66,930,000 after purchasing an additional 666,617 shares during the last quarter. Point72 DIFC Ltd raised its stake in shares of Bruker by 4,875.9% during the 3rd quarter. Point72 DIFC Ltd now owns 470,171 shares of the medical research company's stock worth $32,470,000 after buying an additional 460,722 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Bruker by 1,933.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 410,234 shares of the medical research company's stock worth $28,331,000 after buying an additional 390,057 shares in the last quarter. Finally, State Street Corp grew its stake in Bruker by 9.6% in the 3rd quarter. State Street Corp now owns 3,627,300 shares of the medical research company's stock valued at $250,501,000 after acquiring an additional 318,808 shares during the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on BRKR shares. UBS Group assumed coverage on shares of Bruker in a research report on Tuesday, December 10th. They issued a "neutral" rating and a $66.00 price target on the stock. Guggenheim reiterated a "buy" rating on shares of Bruker in a report on Monday, February 24th. The Goldman Sachs Group upgraded Bruker from a "sell" rating to a "neutral" rating and set a $60.00 price objective on the stock in a research report on Thursday, December 5th. Stifel Nicolaus dropped their price objective on Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a research report on Friday, February 14th. Finally, Barclays cut their target price on shares of Bruker from $69.00 to $65.00 and set an "overweight" rating for the company in a research note on Monday, February 10th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $70.50.
View Our Latest Stock Analysis on BRKR
Bruker Trading Down 3.2 %
Shares of BRKR traded down $1.37 during mid-day trading on Friday, hitting $42.08. The company had a trading volume of 1,207,623 shares, compared to its average volume of 1,358,821. Bruker Co. has a 1-year low of $41.80 and a 1-year high of $94.35. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. The business's 50-day simple moving average is $50.54 and its 200-day simple moving average is $57.01. The stock has a market cap of $6.38 billion, a PE ratio of 55.37, a P/E/G ratio of 2.16 and a beta of 1.18.
Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. Sell-side analysts forecast that Bruker Co. will post 2.69 earnings per share for the current year.
Bruker Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Monday, March 17th were issued a $0.05 dividend. The ex-dividend date was Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.48%. Bruker's dividend payout ratio (DPR) is 26.32%.
About Bruker
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Further Reading
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
